# Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

> **NCT02045030** · PHASE2 · TERMINATED · sponsor: **CR-CSSS Champlain-Charles-Le Moyne** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** aflibercept + FOLFIRI

## Key facts

- **NCT ID:** NCT02045030
- **Lead sponsor:** CR-CSSS Champlain-Charles-Le Moyne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Drug (Aflibercept) no longuer available for the study
- **Last updated:** 2016-11-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045030, "Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02045030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*